Gains in Heart Health Only Experienced by Higher-Income Populations
FRIDAY, April 19, 2024 -- Only higher-income populations experienced improvements in cardiovascular health from 1988 to 2018, according to a study published online April 3 in Circulation: Cardiovascular Quality and Outcomes.
Nicholas K.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
AAN: Half of Premenopausal Women Have Menstrual Migraines
FRIDAY, April 19, 2024– More than half of premenopausal women report menstrual migraine (MM), according to a study presented at the annual meeting of the American Academy of Neurology, held from April 13 to 18 in Denver.
Jessica Cirillo,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
2000-2010 to 2011-2022 Saw Increase in Lifetime Risk for A-Fib
FRIDAY, April 19, 2024 -- From 2000 to 2022, there was an increase in the lifetime risk for atrial fibrillation, according to a study published online April 17 in The BMJ.
Nicklas Vinter, M.D., Ph.D., from Aalborg University in Denmark, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Recommendations Developed to Prepare Patients for Oral Immunotherapy
FRIDAY, April 19, 2024 -- In a research article published online April 8 in the Journal of Allergy and Clinical Immunology, consensus recommendations are presented for preparing and counseling patients and caregivers prior to oral immunotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Risk Prediction Model Accurate for Chronic Kidney Disease
FRIDAY, April 19, 2024 -- For individuals with moderate-to-severe chronic kidney disease (CKD), a model, KDpredict, can accurately predict the risk for kidney failure and death, according to a study published online April 15 in The BMJ.
Ping Liu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Excessive Internet Use Tied to More Absences for Teens
FRIDAY, April 19, 2024 -- Excessive internet use is associated with an increased risk for both unexcused and medical absences from school among teenagers, according to a study published online April 16 in the Archives of Disease in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Mortality Down for Rectal Cancer Surgery at NAPRC-Accredited Hospitals
FRIDAY, April 19, 2024 -- National Accreditation Program for Rectal Cancer (NAPRC)-accredited hospitals have lower risk-adjusted mortality and morbidity for patients undergoing major rectal cancer surgery, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
South Jersey hospital receives $4 million 'multi-generational' gift
In recognition of the gift, the hospital has renamed its pediatric cardiology department. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 19, 2024 Category: Pharmaceuticals Authors: John George Source Type: news
Measure 110 providers report steep growth in clients seeking substance use services
Newly released data show that more people are getting peer support and harm reduction. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 19, 2024 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
Introducing Harlo: Pioneering a New Era in Health Beverages
Siamak Taghaddos Launches A 3-in-1 Wellness Drink Mix Redefining Wellness LOS ANGELES, April 19, 2024 /PRNewswire-PRWeb/ -- Drink Harlo LLC, a groundbreaking wellness brand, announces the launch of its flagship product, Harlo—a unique 3-in-1 drink mix crafted to elevate hydration, energy... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 19, 2024 Category: Pharmaceuticals Tags: PDT Source Type: news
Ziegler Advises Retirement Housing Foundation on The Sale Of 15-Community Portfolio
CHICAGO, April 19, 2024 /PRNewswire-PRWeb/ -- Ziegler, a specialty investment bank, is pleased to announce its role as exclusive sell-side advisor to Retirement Housing Foundation (hereafter "RHF") on the sale of its 15-community senior living portfolio located across six states:... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 19, 2024 Category: Pharmaceuticals Tags: SCZ Source Type: news
Private equity ownership rises among health providers
There's been a national surge in the number of investment firms acquiring health care providers – with South Florida among the top regions fueling that trend. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 19, 2024 Category: Pharmaceuticals Authors: Eman Elshahawy Source Type: news
InHome Connect and Vertedge Health Analytics announce a data-driven partnership to enhance the delivery of palliative care.
This partnership between Vertedge Health Analytics and InHome Connect utilizes data analytics to align patients in value-based care plans with palliative care services, aiming to improve patient care experiences, minimize unnecessary care utilization, and ultimately lower the total cost... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 19, 2024 Category: Pharmaceuticals Tags: LIC Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Investor Update - April 19, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with abouthalf of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2TheNational Comprehensive Cancer Network ® (NCCN®)Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selectionBasel, 19 April 2024 - Roche (SIX: RO,...
Source: Roche Media News - April 19, 2024 Category: Pharmaceuticals Source Type: news
